• PRAGUE-18 Hints at Risk-Based Personalized DAPT After STEMI-PCI Discharge

    11 monthes ago - By Medscape

    Those who substituted clopidogrel for prasugrel or ticagrelor to avoid their steep out-of-pocket expense in the Czech trial, a lower-risk group as it turned out, didn't have more ischemic events.
    Medscape Medical News
    Read more ...


  • Prasugrel, ticagrelor yield similar 1-year outcomes; switch to clopidogrel safe in STEMI

    11 monthes ago - By Healio

    ANAHEIM, Calif. - Patients who underwent PCI for STEMI had similar outcomes at 1 year regardless of assignment to prasugrel or ticagrelor, according to a substudy of the PRAGUE-18 trial. Moreover, patients who switched from either antiplatelet therapy to clopidogrel after discharge had no increased risk for ischemic events.
    As Cardiology Today's Intervention previously reported, PRAGUE-18, the first randomized, head-to-head comparison of prasugrel vs. ticagrelor , showed no difference in outcomes between the therapies at 7
    Read more ...